STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing...
Hence then, the article about bioarctic receives orphan drug designation for exidavnemab the us was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic receives Orphan Drug Designation for exidavnemab the US )
Also on site :
- Hollywood mourns loss of beloved makeup artist Jasen Kaplan
- Suspected mountain lion attack in Colorado mountains under investigation
- Rose Parade Viewers 'Floored' by 'Disaster' Finale Performance: 'Yikes'